We also found >2 fold signal in genes previously identified as methylated in prostate cancer such as CDKN2A (average of 15.8 fold enrichment), RUNX3 (2.8 fold), and PTGS2 (2.9 fold). The gene discussed is RUNX3; the disease is prostate cancer.